Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)

Trial Profile

Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 May 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IRENE; IRENE-study - NVALT16
  • Most Recent Events

    • 02 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 02 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017.
    • 14 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top